Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans

Aging

Volumn 3, Issue 5, 2011, Pages 533-542

  Weiss, Edward P ^a,b   Villareal, Dennis T ^a,c   Fontana, Luigi ^a,d   Han Dong Ho, D H ^a   Holloszy, John O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Aging; Insulin resistance; Interleukin 6; Tumor necrosis factor

Indexed keywords

CYTOKINE; PLACEBO; PRASTERONE;

AGED; AGING; ANIMAL; ARTICLE; BLOOD; BLOOD ANALYSIS; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; IMMUNOLOGY; INFLAMMATION; INSULIN RESISTANCE; MALE; PHYSIOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

AGED; AGING; ANIMALS; BLOOD CHEMICAL ANALYSIS; CYTOKINES; DEHYDROEPIANDROSTERONE; ENERGY INTAKE; EXERCISE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; PLACEBOS; QUESTIONNAIRES;

EID: 80053116974     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100327     Document Type: Article

References (44)

1. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann N Y Acad Sci 1995; 774: 29-46.
2. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992; 75: 1002-1004.
3. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59 551-555.
4. Enomoto M, Adachi H, Fukami A, Furuki K, Satoh A, Otsuka M, Kimagae S, Nanjo Y, Shigetoh Y, Imaizumi T. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). J Am Geriatr Soc 2008; 56 994-998.
5. Mohan PF, Ihnen JS, Levin BE, Cleary MP. Effects of dehydroepiandrosterone treatment in rats with diet-induced obesity. J Nutr 1990; 120 1103-1114.
6. Hansen PA, Han D-H, Nolte LA, Chen M, Holloszy JO. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high fat diet. Am J Physiol:Regulatory 1997; 273 R1704-R1708.
7. Han D-H, Hansen PA, Chen MM, Holloszy JO. DHEA treatment reduces fat accumulation and protects against insulin resistance in male rats. J Gerontol Biol Sci 1998; 53 B19-B24.
8. Cleary MP, Zabel T, Sartin JL. Effects of short-term dehydroepiandrosterone treatment on serum and pancreatic insulin in Zucker rats. J Nutr 1988; 118 382-387.
9. Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H. Dehydroepiandrosterone decreases serum tumor necrosis factor-a and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endo 1998; 139 3249-3253.
10. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA 2004; 292 2243-2248.
11. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. DiabetesCare 1999; 22 1462-1470.
12. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr 2009; 89 1459-1467.
13. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005; 54 765-769.
14. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, Miyamoto S, Nakano M, Ogawa H. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003; 88 3190-3195.
15. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, Basile G, Nicita-Mauro V, Cucinotta D. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001; 145 457-461.
16. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Man CD, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Eng J Med 2006; 355 1647-1659.
17. Basu R, Man CD, Campioni M, Basu A, Nair KS, Jensen MD, Khosla S, Klee G, Toffolo G, Cobelli C, Rizza RA. Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. Diabetes 2007; 56 753-766.
18. Matthews DR, Hosker JP, Rodenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 412-419.
19. Peters JM, Zhou Y-C, Ram PA, Lee SST, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor a required for gene induction by dehydroepiandrosterone-3b-sulfate. Mol Pharmacol 1996; 50 67-74.
20. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273 32833-32841.
21. LeFebvre P, Chinetti G, Fruchart J-C, Staels B. Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116 571-580.
22. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Schölmerich J, Falk W, Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. 83 1998; 2017.
23. Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Nakashima N. Dehydroepiandrosterone-sulfate inhibits nuclear factor-kB-dependent transcription in hepatocytes, possibly through antioxidant effect. J Clin Endocrinol Metab 2004; 89 3449-3454.
24. Altman R, Motton DD, Kota RS, Rutledge JC. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARa and NF-kB. Vascul Pharmacol 2008; 48 76-84.
25. Gutiérrez G, Mendoza C, Zapata E, Montiel A, Reyes E, Montaño LF, López-Marure R. Dehydroepiandrosterone inhibits the TNFa-induced inflammatory response in human unbilical vein endothelial cells. Atherosclerosis 2007; 190 90-99.
26. Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor a and interleukin-6 in astrocytes. Int J Dev Neurosci 1999; 17 765-775.
27. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132 2169-2180.
28. Fève B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5 305-311.
29. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg H, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004; 109 2197-2202.
30. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. DC 1988; 11 495-499.
31. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wójcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipids and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000; 30 871-878.
32. Mussoni L, Mannucci L, Sirtori C, Pazzucconi F, Bonfardeci G, Cimminiello C, Notarbartolo A, Scafidi V, Bittolo Bon G, Alessandrini P, Nenci G, Parise P, Colombo L, Piliego T, Tremoli E. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis 2000; 148 397-406.
33. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91 1770-1778.
34. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275 16638-16642.
35. Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K, Shimamoto K. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol 2002; 174 321-329.
36. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)- alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001; 50 411-417.
37. Lu M, Patsouris D, Li P, Flores-Riveros J, Frincke JM, Watkins S, Schenk S, Olefsky JM. A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats. Am J Physiol:Endocrin Metab 2010; 298 E1036-E1048.
38. Campbell CS, Caperuto LC, Hirata AE, Araujo EP, Velloso LA, Saad MJ, Carvalho CR. The phosphatidylinositol/AKT/atypical PKC pathway is involved in the improved insulin sensitivity by DHEA in muscle and liver of rats in vivo. Life Sci 2004; 76 57-70.
39. Sato K, Iemitsu M, Aizawa K, Ajisaka R. DHEA improves impaired activation of Akt and PKC zeta/lambda-GLUT4 pathway in skeletal muscle and improves hyperglycaemia in streptozotocin-induced diabetes rats. Acta Physiol (Oxf) 2009; 197 217-225.
40. Morgan DR, Lazarow A. Immunoassay of insulin: two antibody system. Diabetes 1963; 12 115-126.
41. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. DiabetesCare 1995; 18 245-250.
42. Arif H, Racette SB, Villareal DT, Holloszy JO, Weiss EP. Comparison of methods for assessing abdominal adipose tissue from magnetic resonance images. Obesity 2007; 15 2240-2244.
43. Positano V, Gastaldelli A, Sironi AM, Santarelli MF, Lombardi M, Landini L. An accurate and robust method for unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging 2004; 20 684-689.
44. The Aerobics Center Longitudinal Study Physical Activity Questionnaire. Med Sci Sports Exerc 1997; 6(Suppl) 10-14.